

Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

| Summary for ARTG Entry: | 167364 | Cu Luan Cheng Yun Fang A.K.A. Motherhood-FT1 Formula |
|-------------------------|-------------------------------|--|
| ARTG entry for | Medicine Listed | |
| Sponsor | Sun Herbal Pty Lt | td |
| | Unit 5/25 Garema Australia | a Cct, Kingsgrove, NSW, 2208 |
| ARTG Start Date | 8/12/2009 | |
| Product Category | Medicine | |
| Status | Active | |
| Approval Area | Listed Medicines | |

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. Cu Luan Cheng Yun Fang A.K.A. Motherhood-FT1 Formula Product Type Single Medicine Product Effective Date 7/05/2018 Permitted Indications Traditionally used in Chinese medicine to invigorate/activate Blood Traditionally used in Chinese medicine to tonify/nourish/strengthen/replenish Blood

Traditionally used in Chinese medicine to eliminate/reduce/remove/resolve/dissipate blood-stasis

Traditionally used in Chinese medicine to nourish/tonify/warm/boost/invigorate/strengthen kidney-essence/kidney-jing

Traditionally used in Chinese medicine to regulate Qi

Traditionally used in Chinese medicine to calm/soothe/nourish the liver

Indication Requirements

If TCM terminology is used on medicine label, label statement: Talk to a TCM practitioner/health professional if you are unsure if this medicine is right for you.

Product presentation must not imply or refer to liver disease, such as cirrhosis, hepatitis.

Product presentation must not imply or refer to serious cardiovascular conditions.

Product presentation must not imply or refer to kidney disease.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

For practitioner dispensing only.

Page 1 of 2

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information

Produced at 31.08.2021 at 05:16:01 AEST



Australian Government

Department of Health Therapeutic Goods Administration

Additional Product information

| Pack Size/Poison information | Poison Schedule | |
|--|-----------------|--|
| Pack Size | Poison Schedule | |
| Components 1. Formulation 1 | | |
| | | |
| Dosage Form Capsule, hard | | |
| Route of Administration Oral | | |
| Visual Identification | | |
| Active Ingredients | | |
| Angelica polymorpha root Extract dry concentrate | 22.5 mg | |
| Equivalent: Angelica polymorpha (Dry) | 135 mg | |
| Bupleurum falcatum root Extract dry concentrate | 22.5 mg | |
| Equivalent: Bupleurum falcatum (Dry) | 135 mg | |
| Citrus aurantium fruit Extract dry concentrate | 15 mg | |
| Equivalent: Citrus aurantium (Dry) | 90 mg | |
| Cullen corylifolium seed Extract dry concentrate | 22.5 mg | |
| Equivalent: Cullen corylifolium (Dry) | 135 mg | |
| Cuscuta hygrophilae seed Extract dry concentrate | 22.5 mg | |
| Equivalent: Cuscuta hygrophilae (Dry) | 135 mg | |
| Cyperus rotundus rhizome Extract dry concentrate | 22.5 mg | |
| Equivalent: Cyperus rotundus (Dry) | 135 mg | |
| Leonurus sibiricus herb Extract dry concentrate | 22.5 mg | |
| Equivalent: Leonurus sibiricus (Dry) | 135 mg | |
| Ligusticum striatum rhizome Extract dry concentrate | 22.5 mg | |
| Equivalent: Ligusticum striatum (Dry) | 135 mg | |
| Lycopus lucidus herb Extract dry concentrate | 22.5 mg | |
| Equivalent: Lycopus lucidus (Dry) | 135 mg | |
| Paeonia veitchii root Extract dry concentrate | 30 mg | |
| Equivalent: Paeonia veitchii (Dry) | 180 mg | |
| Polygonatum sibiricum root Extract dry concentrate | 22.5 mg | |
| Equivalent: Polygonatum sibiricum (Dry) | 135 mg | |
| Prunus persica seed Extract dry concentrate | 15 mg | |
| Equivalent: Prunus persica (Dry) | 90 mg | |
| Rehmannia glutinosa root Extract dry concentrate | 22.5 mg | |
| Equivalent: Rehmannia glutinosa (Dry) | 135 mg | |
| Salvia miltiorrhiza root and rhizome Extract dry concentrate | 15 mg | |
| Equivalent: Salvia miltiorrhiza (Dry) | 90 mg | |
| Other Ingredients (Excipients) | | |
| hydrolysed gelatin | | |
| soluble maize starch | | |

titanium dioxide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Page 2 of 2

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown. Visit www.tga.gov.au for contact information